{"id":1361,"date":"2023-02-10T12:08:31","date_gmt":"2023-02-10T12:08:31","guid":{"rendered":"https:\/\/blog.trive.com\/?p=1361"},"modified":"2023-02-10T12:08:31","modified_gmt":"2023-02-10T12:08:31","slug":"astrazeneca-plcs-earnings-surprise-tickles-bullish-investors","status":"publish","type":"post","link":"https:\/\/blog.trive.com\/de\/investition\/gewinnwarnung-von-astrazeneca-kitzelt-bullische-investoren\/","title":{"rendered":"Gewinnwarnung von AstraZeneca kitzelt bullische Investoren\u00a0"},"content":{"rendered":"<p>AstraZeneca PLC (LSE: AZN) verzeichnete 2022 ein solides Jahr mit einem rasanten Wachstum der Gesamteinnahmen um 25 %, obwohl der Umsatzr\u00fcckgang bei den Covid-19-Impfstoffen den Gro\u00dfteil des Jahres belastete. Bullische Investoren st\u00fcrzten sich auf die Aktie, nachdem die Gewinne im vierten Quartal den Konsens um 2,74 % \u00fcbertroffen hatten, was den Aktienkurs von AstraZeneca um 3,7 % ansteigen lie\u00df.&nbsp;<\/p>\n\n\n\n<p>Der CEO gab eine positive Prognose f\u00fcr das Jahr 2023 ab und rechnet mit einem zweistelligen Umsatzwachstum (ohne Covid-19-Impfstoffe), das durch einen Rekord von 34 Zulassungen f\u00fcr medizinische Produkte unterst\u00fctzt wird, die auf den wichtigsten M\u00e4rkten verkauft werden sollen. Dar\u00fcber hinaus wird erwartet, dass das Umsatzwachstum in den Schwellenl\u00e4ndern, insbesondere in China, zum gesamten Umsatzwachstum beitragen wird.&nbsp;&nbsp;<\/p>\n\n\n\n<h2><strong>Technische Analyse<\/strong>&nbsp;<\/h2>\n\n\n\n<p>Die positiven Ergebnisse des 3. Quartals 2022 lie\u00dfen den Aktienkurs von AstraZeneca schnell ansteigen. Der Kurs stieg um 9,52 % und erreichte ein Rekordhoch und einen Widerstand bei 118,04 \u00a3 pro Aktie, w\u00e4hrend die Unterst\u00fctzung bei 95,10 \u00a3 pro Aktie lag.&nbsp;<\/p>\n\n\n\n<p>Ein Retracement vom Widerstand f\u00fchrte den Kurs bis zum goldenen Fibonacci-Verh\u00e4ltnis von 61,8 %, bevor eine Ablehnung folgte. Besser als erwartete Gewinne und gesunde Gesch\u00e4ftsgrundlagen lockten weitere Bullen auf den Markt. Bullische Investoren d\u00fcrften die Marke von 118,04 \u00a3 pro Aktie als Ausstiegsmarke ins Visier nehmen, sollten sie sich am Markt beteiligen.&nbsp;<\/p>\n\n\n\n<p>Sollte jedoch das b\u00e4rische Momentum das zinsbullische Momentum auf dem gegenw\u00e4rtigen Niveau \u00fcbertreffen, k\u00f6nnte sich der Kurs umkehren und zur Unterst\u00fctzung bei 95,10 \u00a3 je Aktie zur\u00fcckfinden.&nbsp;&nbsp;<\/p>\n\n\n\n<figure class=\"is-layout-flex wp-block-gallery-1 wp-block-gallery has-nested-images columns-default is-cropped\">\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" loading=\"lazy\" width=\"1024\" height=\"520\" data-id=\"1362\"  src=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/AZN_2023-02-10_12-54-09_fb58d-1024x520.png\" alt=\"\" class=\"wp-image-1362\" srcset=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/AZN_2023-02-10_12-54-09_fb58d-1024x520.png 1024w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/AZN_2023-02-10_12-54-09_fb58d-300x152.png 300w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/AZN_2023-02-10_12-54-09_fb58d-768x390.png 768w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/AZN_2023-02-10_12-54-09_fb58d-1536x780.png 1536w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/AZN_2023-02-10_12-54-09_fb58d-18x9.png 18w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/AZN_2023-02-10_12-54-09_fb58d.png 1834w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/figure>\n\n\n\n<p><\/p>\n\n\n\n<h2><strong>Fundamentalanalyse<\/strong>&nbsp;<\/h2>\n\n\n\n<p>Die \u00c4ngste vor einer Pandemie lie\u00dfen 2022 nach, unterst\u00fctzt durch einen allgemein schw\u00e4cheren Absatz des Impfstoffs Covid-19 (Vaxzevria). Trotz des R\u00fcckgangs der Impfstoffverk\u00e4ufe blieb der Umsatz mit anderen medizinischen Produkten auf hohem Niveau. Das Umsatzwachstum von AstraZeneca in H\u00f6he von 25 % verblasst im Vergleich zu einem Wachstum von 34 % ohne Impfstoffverk\u00e4ufe.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Die solide operative Leistung wurde durch eine Verdreifachung des Betriebsgewinns unterst\u00fctzt, was die operative Gesundheit von AstraZeneca offenbart. Der Cashflow aus dem operativen Gesch\u00e4ft stieg im Jahresvergleich um 46 % und schloss das Jahr mit 12 Mrd. USD gegen\u00fcber 8 Mrd. USD ab. Die Cashflows des Jahres 2023 werden wahrscheinlich durch den im Jahr 2022 erreichten R\u00fcckgang der Schuldverpflichtungen beg\u00fcnstigt, da die Nettoverschuldung um 5,75 % auf 23 Mrd. USD zur\u00fcckging.&nbsp;<\/p>\n\n\n\n<p>Der Umsatz in den Industriel\u00e4ndern macht 60 % des Gesamtumsatzes aus, gefolgt vom Rest der Welt, der 40 % beitr\u00e4gt (davon 13 % in China). In Anbetracht der Tatsache, dass AstraZeneca im Verkauf von Bedarfsg\u00fctern t\u00e4tig ist, ist es unwahrscheinlich, dass das Unternehmen mit ernsthaftem Gegenwind aufgrund der Inflation und deren Beeintr\u00e4chtigung der Verbraucherausgaben konfrontiert wird, insbesondere in entwickelten Volkswirtschaften wie den USA, wo 40 % des Umsatzes verbucht werden.&nbsp;&nbsp;&nbsp;<\/p>\n\n\n\n<p>Nach Abzinsung der k\u00fcnftigen Cashflows ergab sich f\u00fcr AstraZeneca ein Marktwert von 117,20 \u00a3 pro Aktie, was einem Aufschlag von 4,8 % auf den aktuellen Aktienkurs entspricht.&nbsp;&nbsp;&nbsp;<\/p>\n\n\n\n<h2><strong>Zusammenfassung<\/strong>&nbsp;<\/h2>\n\n\n\n<p>Die finanzielle und operative Gesundheit von AstraZeneca im Jahr 2022 wird sich wahrscheinlich bis ins Jahr 2023 fortsetzen. In Verbindung mit den optimistischen Prognosen f\u00fcr 2023 wird der Aktienkurs von AstraZeneca wahrscheinlich nach oben gezogen werden, sofern sich keine wesentlichen negativen gesch\u00e4ftlichen Umst\u00e4nde ergeben.&nbsp;&nbsp;<\/p>\n\n\n\n<p><em>Quellen: AstraZeneca, Reuters, TradingView, Koyfin&nbsp;<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>AstraZeneca PLC (LSE: AZN) delivered a solid 2022 with a blistering 25% growth in total revenues, despite being weighed down by declining sales of Covid-19 vaccines for most of 2022. Bullish traders rushed to buy the stock after Q4 earnings beat consensus by 2.74%, subsequently pushing AstraZeneca&#8217;s share price up 3.7%.&nbsp; The CEO gave positive [&hellip;]<\/p>","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0 - Trive Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.trive.com\/de\/investition\/gewinnwarnung-von-astrazeneca-kitzelt-bullische-investoren\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca PLC (LSE: AZN) delivered a solid 2022 with a blistering 25% growth in total revenues, despite being weighed down by declining sales of Covid-19 vaccines for most of 2022.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.trive.com\/de\/investition\/gewinnwarnung-von-astrazeneca-kitzelt-bullische-investoren\/\" \/>\n<meta property=\"og:site_name\" content=\"Trive Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-10T12:08:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/Folie1-4.png\" \/>\n\t<meta property=\"og:image:width\" content=\"720\" \/>\n\t<meta property=\"og:image:height\" content=\"405\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\" \/>\n<meta name=\"twitter:description\" content=\"AstraZeneca PLC (LSE: AZN) delivered a solid 2022 with a blistering 25% growth in total revenues, despite being weighed down by declining sales of Covid-19 vaccines for most of 2022.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/Folie1-4.png\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0\",\"datePublished\":\"2023-02-10T12:08:31+00:00\",\"dateModified\":\"2023-02-10T12:08:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/\"},\"wordCount\":463,\"publisher\":{\"@id\":\"https:\/\/blog.trive.com\/#organization\"},\"articleSection\":[\"Investment\"],\"inLanguage\":\"de-DE\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/\",\"url\":\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/\",\"name\":\"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0 - Trive Blog\",\"isPartOf\":{\"@id\":\"https:\/\/blog.trive.com\/#website\"},\"datePublished\":\"2023-02-10T12:08:31+00:00\",\"dateModified\":\"2023-02-10T12:08:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/blog.trive.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.trive.com\/#website\",\"url\":\"https:\/\/blog.trive.com\/\",\"name\":\"Trive Blog\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/blog.trive.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.trive.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/blog.trive.com\/#organization\",\"name\":\"Trive Blog\",\"url\":\"https:\/\/blog.trive.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png\",\"contentUrl\":\"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png\",\"width\":723,\"height\":199,\"caption\":\"Trive Blog\"},\"image\":{\"@id\":\"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\/\/blog.trive.com\/de\/author\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0 - Trive Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.trive.com\/de\/investition\/gewinnwarnung-von-astrazeneca-kitzelt-bullische-investoren\/","og_locale":"de_DE","og_type":"article","og_title":"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors","og_description":"AstraZeneca PLC (LSE: AZN) delivered a solid 2022 with a blistering 25% growth in total revenues, despite being weighed down by declining sales of Covid-19 vaccines for most of 2022.","og_url":"https:\/\/blog.trive.com\/de\/investition\/gewinnwarnung-von-astrazeneca-kitzelt-bullische-investoren\/","og_site_name":"Trive Blog","article_published_time":"2023-02-10T12:08:31+00:00","og_image":[{"width":720,"height":405,"url":"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/Folie1-4.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_title":"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors","twitter_description":"AstraZeneca PLC (LSE: AZN) delivered a solid 2022 with a blistering 25% growth in total revenues, despite being weighed down by declining sales of Covid-19 vaccines for most of 2022.","twitter_image":"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/Folie1-4.png","twitter_misc":{"Verfasst von":"","Gesch\u00e4tzte Lesezeit":"3 Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/#article","isPartOf":{"@id":"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/"},"author":{"name":"","@id":""},"headline":"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0","datePublished":"2023-02-10T12:08:31+00:00","dateModified":"2023-02-10T12:08:31+00:00","mainEntityOfPage":{"@id":"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/"},"wordCount":463,"publisher":{"@id":"https:\/\/blog.trive.com\/#organization"},"articleSection":["Investment"],"inLanguage":"de-DE"},{"@type":"WebPage","@id":"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/","url":"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/","name":"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0 - Trive Blog","isPartOf":{"@id":"https:\/\/blog.trive.com\/#website"},"datePublished":"2023-02-10T12:08:31+00:00","dateModified":"2023-02-10T12:08:31+00:00","breadcrumb":{"@id":"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blog.trive.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/blog.trive.com\/#website","url":"https:\/\/blog.trive.com\/","name":"Trive Blog","description":"","publisher":{"@id":"https:\/\/blog.trive.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.trive.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/blog.trive.com\/#organization","name":"Trive Blog","url":"https:\/\/blog.trive.com\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/","url":"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png","contentUrl":"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png","width":723,"height":199,"caption":"Trive Blog"},"image":{"@id":"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/blog.trive.com\/de\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/posts\/1361"}],"collection":[{"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/comments?post=1361"}],"version-history":[{"count":2,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/posts\/1361\/revisions"}],"predecessor-version":[{"id":1365,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/posts\/1361\/revisions\/1365"}],"wp:attachment":[{"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/media?parent=1361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/categories?post=1361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/tags?post=1361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}